An excellent, balanced thread on imetelstat. G-CSF usage 36% vs 3% Platelet transfusion 18% versus 2% Reduce blood transfusions, but increase platelets transfusions and G-CSF? 😕 I am not against options or approvals, my intent is to educate and highlight nuances/limitations.

Congratulations !! Abdul Moiz Khan Maria Levitin Richa Parikh and Dr. Chi who graduated from Karmanos Hematology/Oncology Fellowship fellowship Karmanos Cancer Institute.

Glad to share that our real world analysis on Isovolumic Hemodilution RBC exchange in patients with SCD has been accepted for presentation at AABB 2024 annual meeting. Grateful to mentors for their constant support ! Vijendra Singh @ Asif Alavi AABB ASH

A very well deserved award for Dr. Schiffer ! karmanos.org/karmanos/news/…

Congratulations Dr. Charles Schiffer, retired Karmanos hematologist and medical oncologist, for receiving one of two Mentor Awards from the American Society of Hematology! #YourBestChance To read more about this accomplishment, click below. mclarenhealthcare.org/3zRYbjt

Dr. Jay Yang Karmanos Cancer Institute starting off the Annual Lymphoma Symposium with a great presentation on CLL ! Continuos vs time limited therapy for frontline CLL

🚨Melphalan Dose in FluMel RIC condition regimen for AML and MDS: Mel100 vs Mel140 associated with lower risk of GI toxicity and cGVHD with no impact on relapse,NRM and OS. ⁦Transplantation and Cellular Therapy Journal⁩ ⁦Moffitt Cancer Center⁩ ⁦مستشفى الملك فهد التخصصي بالدمام⁩ astctjournal.org/article/S2666-…

It’s a proud moment for us! ASH awards 2024 Mentor award to Dr.Schiffer. #ASH24 ASH Wayne State University Karmanos Cancer Institute

Please check out our poster at 3717 #ASH 24.Grateful to present on “Mortality characteristics of RSV Hospitalisation among patients with Haematological malignancies-Paving way for Universal RSV Vaccination”Thanks to my mentors! ⁦Vijendra Singh⁩ ⁦Karmanos Hematology/Oncology Fellowship⁩⁦

Please stop by our poster at 3717 #ASH24 “Mortality characteristics of RSV Hospitalisations” ✔️Statistically significant higher mortality rates in hematological malignancies in general and NHL subgroup under 60 years of age ! ⁦Vijendra Singh⁩ ⁦Karmanos Hematology/Oncology Fellowship⁩ ⁦

Happy to share that our article on “Acquired haemophilia - Readmissions and outcomes” is accepted for publication in VTH- ASH journal. Thanks to my mentors for the support ⁦Vijendra Singh⁩ aditi Sharma ⁦Karmanos Hematology/Oncology Fellowship⁩ ⁦Karmanos Cancer Institute⁩ ⁦Trinity Health / Wayne State Internal Medicine⁩

Excited to share that our abstract accepted for ASCO residents forum ! Cannot wait for final ASCO abstract results ! ⁦ASCO⁩ Thanks to my mentors for the opportunity! ⁦Vijendra Singh⁩ ⁦Ibrahim Azar, MD⁩ ⁦Karmanos Hematology/Oncology Fellowship⁩ ⁦Trinity Health / Wayne State Internal Medicine⁩

Mark your calendars! The MSHO Hematology Jeopardy Quiz kicks off Fri, April 12, 2025—fun, learning, & heme vibes await! #MSHOJeopardy msho.org/aws/MSHO/asset…

Hot off the press ! Outcomes of respiratory syncytial virus infection among hospitalized adults with hematological malignancies. Forever grateful to my mentors ! Vijendra Singh Geetha Krishnamoorthy tandfonline.com/doi/full/10.10…

Check out our Poster #63 #ASCO discussing the largest real-world study on t-MN incidence with RAI (Pluvicto and Lutathera) in n=2370. Overall risk is 1.6% at a median follow-up of 27.3 months: 1.9% with Lutathera, 1.2% with Pluvicto.Nikhil Vojjala, MD Vijendra Singh